Analyst Ratings For Aurinia Pharmaceuticals (NASDAQ:AUPH)
Today, Cantor Fitzgerald reiterated its Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) with a price target of $14.00.
There are 7 buy ratings on the stock.
The current consensus rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) is Buy (Score: 3.00) with a consensus target price of $11.00 per share, a potential 57.14% upside.
Some recent analyst ratings include
- 4/21/2017-Cantor Fitzgerald Reiterated Rating of Buy.
- 4/11/2017-FBR & Co Reiterated Rating of Outperform.
- 11/4/2016-Bloom Burton Reiterated Rating of Buy.
- 11/2/2016-Mackie Reiterated Rating of Buy.
Dividend information for Aurinia Pharmaceuticals (NASDAQ:AUPH)
About Aurinia Pharmaceuticals (NASDAQ:AUPH)
Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.
Recent Trading Activity for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Shares of Aurinia Pharmaceuticals closed the previous trading session at 7.00 up +0.08 1.16% with 5,322,190 shares trading hands.